Using blood tests to predict outcomes in patients with localized pancreatic cancer
Official title: Implementing Non-invasive Circulating Tumor DNA and Circular DNA Analysis in Patients With Localized Pancreatic Cancer to Optimize the Pre- and Postoperative Treatment: Predicting Recurrence and Survival and Changing Prognosis Over Time
Run by Copenhagen University Hospital at Herlev · NCT05788744 · Data updated 2026-11-12
This study is testing if blood tests that look for specific DNA can help predict how well patients with localized pancreatic cancer will do after surgery and improve their follow-up care.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Copenhagen University Hospital at Herlev Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 5 sites (Aalborg and 4 other locations) |
| Status | Recruiting |
| Started | January 1, 2023 |
| Main results expected | January 2029 |
| Study ends | January 2032 |
| Registry record updated | March 27, 2026 |
| Trial ID | NCT05788744 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients with suspected PDAC tumor stages I-III who are scheduled for surgical resection.
✕Probably not a fit
Patients with other cancers or those unlikely to comply with the study protocol may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to evaluate the effectiveness of plasma circulating tumor DNA (ctDNA) and circular DNA (eccDNA) in predicting early recurrence and overall survival in patients with localized pancreatic ductal adenocarcinoma (PDAC) scheduled for surgical resection. The study includes an observational component where blood samples will be collected at various intervals, and an interventional randomized trial comparing ctDNA-guided surveillance to standard surveillance in patients without recurrence four months post-surgery. The goal is to determine if ctDNA can enhance patient outcomes by identifying those who will benefit from surgery and improving surveillance methods.
Why it matters
Potential benefit: If successful, this study could lead to improved survival rates and quality of life for patients with localized pancreatic cancer.
How similar studies have gone: Other studies have shown promise in using ctDNA for cancer monitoring, suggesting potential success for this approach in pancreatic cancer.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Sub-study 1: Suspicion of PDAC tumor stage I-III, scheduled for pancreatic resection, with or without preoperative neoadjuvant chemotherapy. * Sub-study 2: . * PDAC tumor stage I-III * Has received intended curative resection (R0/R1) of PDAC * No signs of local recurrence or metastatic disease at a CT scan 4 months after the operation Exclusion Criteria: * Other cancers (excluding skin cancer other than melanoma) later than 3 years before inclusion * Patients who are unlikely to comply with the protocol, inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study
Where it's running
-
Aalborg Universitetshospital
Aalborg, Denmark Recruiting -
Aarhus Universitetshospital
Aarhus, Denmark Recruiting -
Copenhagen University Hospital - Rigshospitalet
Copenhagen, Denmark Recruiting -
Copenhagen University Hospital - Herlev and Gentofte
Herlev, Denmark Recruiting -
Odense Universitetshospital
Odense, Denmark Recruiting
Study contacts
- Principal investigator: Julia S Johansen, MD — Copenhagen University Hospital - Herlev and Gentofte
- Study coordinator: Julia S Johansen, MD
- Email: Julia.sidenius.johansen@regionh.dk
- Phone: +45 38689241
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Predicting pancreatic fistula after pancreaticoduodenectomy
This project will try to find which before-, during-, and after-surgery factors predict clinically significant pancreatic fistula in adults having pancreaticoduodenectomy for pancreatic or periampullary tumors.
-
Combining NovoTTF-200T(P) with Gemcitabine and Nab-Paclitaxel for Treating Resectable Pancreatic Cancer
This study is testing if a new treatment combining NovoTTF-200T(P) with two chemotherapy drugs can help people with resectable pancreatic cancer do better and have successful surgery.
-
Comparing chemotherapy before and after surgery for pancreatic cancer
This study is testing whether giving chemotherapy before surgery can help people with resectable pancreatic cancer do better and live longer, especially in Asian patients.
-
Combining chemotherapy and radiation before surgery for localized pancreatic cancer
This study is testing if giving chemotherapy and radiation before surgery can help people with localized pancreatic cancer have better chances of completely removing the cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.